Lonza to acquire Exosomics Service Unit in Siena, Italy to expand development service offering in exosome bioprocessing Expertise in exosomes isolation and characterization will drive innovation in this field Lonza, […]
Autor: Firma Lonza Group Ltd.
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
Lonza to acquire and operate Codiak’s Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline Lonza and Codiak to establish a Center of Excellence focused on […]
Capital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable Value Creation Through Long-Term Growth
At its Capital Markets Day, Lonza outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation Accelerated, de-risked, long-term investment program will drive sustainable business growth […]
Lonza Invests to Expand Drug Product Development and Manufacturing Services in Switzerland
. Lonza will invest to expand its drug product manufacturing network in Switzerland The investment will include installation of a new aseptic fill and finish line in Stein and the […]
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
. Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon® platform at the C3i Center Inc (C3i) in Montreal Transitioning to Lonza’s Cocoon® Platform enabled […]
Philippe Deecke appointed as Chief Financial Officer of Lonza Group
Lonza appoints Philippe Deecke as CFO and member of the Lonza Group Executive Committee Philippe brings a wealth of experience from a 30-year career, which includes senior leadership roles […]
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of […]
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by […]
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
. Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal […]
Lonza Completes Divestment of Specialty Ingredients Business
. Lonza announced today the completion of the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion. […]